INTERVEXION THERAPEUTICS
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. Their lead clinical asset is IXT-m200, a monoclonal antibody directed against methamphetamine, which acts by re-partitioning methamphetamine away from its sites of action in the CNS. IXT-m200 has received US FDA Fast Track Designation, and is being studied in an ongoing Phase 2 proof-of-concept study (STAMPOUT; NCT03336866). They are also developing a novel vaccine (IXT-v100) against methamphetamine, which is in Preclinical Development.
INTERVEXION THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Founded:
2004-01-01
Address:
Little Rock, Arkansas, United States
Country:
United States
Website Url:
http://www.intervexion.com
Total Employee:
51+
Status:
Active
Contact:
501.554.2377
Total Funding:
52.8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Mobile Non Scaleable Content Sitelinks Search Box Organization Schema Yoast WordPress SEO Plugin Yoast SEO Premium Yoast Plugins
Similar Organizations
Adrenomed
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Ascentage Pharma
Ascentage is a clinical-stage biopharmaceutical company that develops drugs for the treatment of cancer.
Cerebral Therapeutics
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Enteris BioPharma
Enteris BioPharma is a privately held, clinical stage biopharmaceutical company
Inversago Pharma
Inversago Pharma is a specialized, preclinical-stage biotech company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
Ocugen
Ocugen is a clinical stage biopharmaceutical company.
UNION therapeutics A/S
UNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company.
Current Employees Featured
Founder
Investors List
National Institutes of Health
National Institutes of Health investment in Grant - InterveXion Therapeutics
National Institutes of Health
National Institutes of Health investment in Grant - InterveXion Therapeutics
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - InterveXion Therapeutics
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - InterveXion Therapeutics
National Institutes of Health
National Institutes of Health investment in Grant - InterveXion Therapeutics
National Institutes of Health
National Institutes of Health investment in Grant - InterveXion Therapeutics
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - InterveXion Therapeutics
National Institutes of Health
National Institutes of Health investment in Grant - InterveXion Therapeutics
National Institute on Drug Abuse (NIDA)
National Institute on Drug Abuse (NIDA) investment in Grant - InterveXion Therapeutics
Official Site Inspections
http://www.intervexion.com Semrush global rank: 9.72 M Semrush visits lastest month: 114
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "InterveXion Therapeutics"
InterveXion Therapeutics - Crunchbase Company …
InterveXion is a privately-held clinical-stage biopharmaceutical company developing novel product candidates for the treatment of addiction disorders. …See details»
InterveXion Therapeutics - LinkedIn
InterveXion Therapeutics | 268 followers on LinkedIn. Binding methamphetamine to release people from addiction | Privately held biotechnology company developing therapies for substance use disorders.See details»
InterveXion Therapeutics - Products, Competitors, Financials, …
InterveXion Therapeutics is a privately held clinical-stage biotech company focused on developing therapies for methamphetamine use disorder. The company offers a range of treatments …See details»
InterveXion Therapeutics - Funding, Financials, Valuation & Investors
InterveXion Therapeutics is funded by 2 investors. National Institutes of Health and National Institutes of Health are the most recent investors. Which investors participated in the most …See details»
InterveXion Therapeutics - Overview, News & Similar companies ...
Apr 3, 2022 View InterveXion Therapeutics (www.intervexion.com) location in Arkansas, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Intervexion Therapeutics, LLC. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Intervexion Therapeutics, LLC. of Little Rock, AR. Get the latest business insights from Dun & Bradstreet.See details»
InterveXion Therapeutics LLC - Drug pipelines, Patents ... - Patsnap
Explore InterveXion Therapeutics LLC with its drug pipeline, therapeutic area, technology platform, 5 clinical trials, 3 news, Drug:Ch-mAb7F9.See details»
InterveXion Therapeutics - Contacts, Employees, Board Members, …
InterveXion Therapeutics is a privately-held clinical-stage biopharmaceutical companySee details»
InterveXion - Craft
InterveXion Therapeutics is a biotechnology company developing therapies for substance use disorders. It offers clinical asset IXT-m200, a monoclonal antibody directed against …See details»
InterveXion Awarded Federal Grant to Fund Phase 2 Study for ...
Oct 4, 2021 InterveXion is the leading biopharmaceutical company developing immunotherapies for patients with methamphetamine use disorder. InterveXion’s lead product, IXT-m200, is a …See details»
InterveXion Therapeutics - PMC
Mar 8, 2017 InterveXion Therapeutics was founded in 2004, based on technology discovered at and licensed from the University of Arkansas for Medical Sciences. We are located in Little …See details»
InterveXion Therapeutics CEO, Founder, Key Executive Team, …
Explore {InterveXion Therapeutics's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»
Clinical - InterveXion
Jul 5, 2022 InterveXion to Present Positive Phase 2 STAMPOUT Study Data at Upcoming CPDD Meeting STAMPOUT is the first positive Phase 2 proof-of-concept trial for an anti …See details»
InterveXion - CoBee Company Profile & Funding Rounds
InterveXion is an Arkansas-based biopharmaceutical company that develops and commercializes novel products for the treatment of addiction disorders.See details»
InterveXion Therapeutics LLC (InterveXion Therapeutics LLC) - 药物 …
了解InterveXion Therapeutics LLC (InterveXion Therapeutics LLC)公司的药物管线，治疗领域，技术平台，以及它的5项临床试验, 2篇新闻，药物:Ch-mAb7F9。See details»
InterveXion Therapeutics, a UAMS Startup, Receives $14.5
Jan 29, 2015 LITTLE ROCK – A University of Arkansas for Medical Sciences (UAMS) BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants …See details»
InterveXion’s Competitors, Revenue, Number of Employees
InterveXion’s Profile, Revenue and Employees. InterveXion is an Arkansas-based biopharmaceutical company that develops and commercializes novel products for the …See details»
Full article: InterveXion Therapeutics - Taylor & Francis Online
Mar 8, 2017 InterveXion Therapeutics was founded in 2004, based on technology discovered at and licensed from the University of Arkansas for Medical Sciences. We are located in Little …See details»
CoreWeave - Governance - Board of Directors
Michael Intrator is one of our co-founders and has served as Chairman of our board of directors and as our Chief Executive Officer and President since September 2017. Previously, from …See details»
InterveXion to Present Positive Phase 2 STAMPOUT Study Data at …
STAMPOUT is the first positive Phase 2 proof-of-concept trial for an anti-METH antibodyLITTLE ROCK, ARKANSAS, USA, April 4, 2022 /EINPresswire.com/ -- InterveXion Therapeutics, a …See details»